Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,030 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy
Interventions
NSHO-101
Drug
Lead sponsor
Ensho Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Conditions
COVID 19
Interventions
ALG-097558
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Receptor Imaging in Mood Disorders

NCT00116077
Conditions
Mood Disorders, Depressive Disorder, Major, Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Subject, Human Papillomavirus Infection
Interventions
carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

NCT03965130
Conditions
Healthy Participants
Interventions
Glucagon, Control Study
Biological · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Interventions
Miricorilant, Fluvoxamine
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

NCT04485039
Conditions
Smallpox
Interventions
Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Conditions
Healthy
Interventions
[11C]JMJ-129-d2
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 105 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Safety and Pharmacokinetics of Intravenous Baclofen
Interventions
Intravenous baclofen
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of ASC42 With Atorvastatin

NCT05464628
Conditions
Healthy
Interventions
Atorvastatin, ASC42
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Siemens 3T PRISMA MR Scanner, PET/CT Scanner, Suvorexant, Placebo
Device · Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers

NCT00622375
Conditions
Healthy
Interventions
mesalamine
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1a Study of PMN310 In Healthy Volunteers

NCT06105528
Conditions
Healthy Participants
Interventions
PMN310, Placebo
Drug
Lead sponsor
ProMis Neurosciences, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Conditions
Obesity, Metabolic Disease
Interventions
Xla1, Placebo
Drug
Lead sponsor
YSOPIA Bioscience
Industry
Eligibility
19 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Rift Valley Fever
Interventions
IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3, IDB-011 dose level 4, IDB-011 dose level 5, Placebo
Drug · Other
Lead sponsor
IDBiologics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Healthy Volunteers
Interventions
Digoxin, Vandetanib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Muscular Atrophy, Spinal
Interventions
risdiplam, omeprazole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Conditions
HIV-1-infection
Interventions
ibalizumab-uiyk
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

NCT01894165
Conditions
Molybdenum Cofactor Deficiency (MoCD), Rare Autosomal Recessive Disorder, Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)
Interventions
ALXN1101, Placebo
Drug
Lead sponsor
Origin Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland